Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations.

Lowe SH, Wensing AM, Droste JA, ten Kate RW, Jurriaans S, Burger DM, Borleffs JC, Lange JM, Prins JM.

HIV Clin Trials. 2006 Nov-Dec;7(6):285-90.

PMID:
17197376
2.

Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.

Taylor S, van Heeswijk RP, Hoetelmans RM, Workman J, Drake SM, White DJ, Pillay D.

AIDS. 2000 Sep 8;14(13):1979-84.

PMID:
10997403
3.

Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.

Ghosn J, Chaix ML, Peytavin G, Bresson JL, Galimand J, Girard PM, Raffi F, Cohen-Codar I, Delfraissy JF, Rouzioux C.

J Antimicrob Chemother. 2008 Jun;61(6):1344-7. doi: 10.1093/jac/dkn098. Epub 2008 Mar 13.

PMID:
18343806
4.

Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.

Lowe SH, van Leeuwen E, Droste JA, van der Veen F, Reiss P, Lange JM, Burger DM, Repping S, Prins JM.

Ther Drug Monit. 2007 Oct;29(5):566-70.

PMID:
17898645
5.

Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B.

HIV Clin Trials. 2002 Jan-Feb;3(1):27-35.

PMID:
11819183
6.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
7.

Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma.

Lorello G, la Porte C, Pilon R, Zhang G, Karnauchow T, MacPherson P.

HIV Med. 2009 Oct;10(9):548-54. doi: 10.1111/j.1468-1293.2009.00725.x. Epub 2009 Jun 8.

8.

Penetration of didanosine in semen of HIV-1-infected men.

Cruciani M, Liuzzi G, Chirianni A, Audagnotto S, Bonora S, Di Biagio A, Sinicco A, Bassetti M, Gatti G.

J Antimicrob Chemother. 2006 Jun;57(6):1244-7. Epub 2006 Mar 23.

PMID:
16556633
9.

Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden.

Pereira AS, Kashuba AD, Fiscus SA, Hall JE, Tidwell RR, Troiani L, Dunn JA, Eron JJ Jr, Cohen MS.

J Infect Dis. 1999 Dec;180(6):2039-43.

PMID:
10558966
10.

Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).

Lowe SH, Wensing AM, Hassink EA, ten Kate RW, Richter C, Schreij G, Koopmans PP, Juttmann JR, van der Tweel I, Lange JM, Borleffs JC.

HIV Clin Trials. 2005 Sep-Oct;6(5):235-45.

PMID:
16306030
11.

Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial.

Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, Ruxrungtham K, Furrer H, Cooper D, Hirschel B, Bernasconi E, Cavassini M, Ebnöther C, Fagard C, Genné D, Khanna N, Perrin L, Phanupak P, Ubolyam S, Vernazza P, Yerly S; Swiss HIV Cohort Study.

AIDS. 2003 Oct 17;17(15):F33-7.

PMID:
14523294
12.

Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir.

Taylor S, Back DJ, Drake SM, Workman J, Reynolds H, Gibbons SE, White DJ, Pillay D.

J Antimicrob Chemother. 2001 Sep;48(3):351-4. Erratum in: J Antimicrob Chemother 2002 Jan;49(1):227.

PMID:
11532998
13.

HIV-1 induction-maintenance at the lymph node level: the "Apollo-97" Study.

Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Chouraqui M, Delbeke E; "Apollo-97 Study".

J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):154-7.

PMID:
11588509
14.

Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.

Taylor S, Reynolds H, Sabin CA, Drake SM, White DJ, Back DJ, Pillay D.

AIDS. 2001 Oct 19;15(15):2051-3.

PMID:
11600838
15.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
16.

Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.

Røge BT, Barfod TS, Kirk O, Katzenstein TL, Obel N, Nielsen H, Pedersen C, Mathiesen LR, Lundgren JD, Gerstoft J.

HIV Med. 2004 Sep;5(5):344-51.

17.

Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.

Dubé MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P; Adult Clinical Trials Group 384.

J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):508-14.

PMID:
17589373
18.

Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.

Reiser M, Salzberger B, Stiepel A, Hoetelmans R, Diehl V, Fätkenheuer G.

Eur J Med Res. 1999 Feb 25;4(2):54-8.

PMID:
10066640
19.

Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission.

Eron JJ, Vernazza PL, Johnston DM, Seillier-Moiseiwitsch F, Alcorn TM, Fiscus SA, Cohen MS.

AIDS. 1998 Oct 22;12(15):F181-9.

PMID:
9814860

Supplemental Content

Support Center